Equilis Prequenza

ประเทศ: สหภาพยุโรป

ภาษา: โรมาเนีย

แหล่งที่มา: EMA (European Medicines Agency)

ซื้อเลย

สารออกฤทธิ์:

ecvine tulpini de virus gripal: A / equine-2 / Africa de Sud / 4/03, A / equine-2 / Newmarket / 2/93

มีจำหน่ายจาก:

Intervet International BV

รหัส ATC:

QI05AA01

INN (ชื่อสากล):

vaccine against equine influenza in horses

กลุ่มบำบัด:

Cai

พื้นที่บำบัด:

virusul influenței ecvine

ข้อบ่งชี้ในการรักษา:

Imunizarea activă a cailor de la vârsta de șase luni împotriva gripei ecvine pentru a reduce semnele clinice și excreția virusului după infecție.

สรุปสินค้า:

Revision: 9

สถานะการอนุญาต:

Autorizat

วันที่อนุญาต:

2005-07-08

แผ่นพับข้อมูลผู้ป่วย

                                B.
PROSPECT
PROSPECT:
EQUILIS PREQUENZA, SUSPENSIE INJECTABILĂ PENTRU CAI
1.
NUMELE ŞI ADRESA DEŢINĂTORULUI AUTORIZAŢIEI DE COMERCIALIZARE
ŞI A DEŢINĂTORULUI AUTORIZAŢIEI DE FABRICARE, RESPONSABIL PENTRU
ELIBERAREA SERIILOR, DACĂ SUNT DIFERITE
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
Olanda
2.
DENUMIREA PRODUSULUI MEDICINAL VETERINAR
Equilis Prequenza, suspensie injectabilă pentru cai.
3.
DECLARAREA (SUBSTANŢEI) SUBSTANŢELOR ACTIVE ŞI A ALTORA
Fiecare doza de 1 ml conține:
SUBSTANŢE ACTIVE
:
Tulpini de virus al Influentei ecvine:
A/equine-2/ South Africa/4/03
50 UA
1
A/equine-2/ Newmarket/2/93
50 UA
Adjuvant
Iscom-Matrix conținînd:
Saponină purificată
375 micrograme
Colesterol
125
micrograme
Fosfatidilcolină
62.5
micrograme
Suspensie clară opalescentă.
4.
INDICAŢIE (INDICAŢII)
Imunizarea activă a cailor începând cu vârsta de 6 luni împotriva
influenţei pentru reducerea semnelor
clinice şi excreţiei de virus după infecţie.
Influenţa
Debutul imunităţii :
2 săptămâni după vaccinarea primară
Durata imunităţii :
5 luni după imunizarea primară
12 luni după prima revaccinare
5.
CONTRAINDICAŢII
Nu este cazul
6.
REACŢII ADVERSE
Poate apare rar o tumefacţie difuză dură sau moale la locul
injectării (max. 5 cm diametru) ce
regresează în 2 zile.
Poate apare rareori o tumefacţie difuză dură sau moale la locul
injectării (max. 5 cm diametru) ce
regresează în 2 zile. Durerea la locul injectării poate apărea în
cazuri rare, care poate duce la disconfort
funcțional temporar (rigiditate).
În cazuri foarte rare poate apare o reacție locală ce depășește
5 cm si este posibil să persiste mai mult
de 2 zile.
Febra, uneori însoțită de letargie și inapetență, poate să
apară în cazuri foarte rare timp de 1 zi și până
la 3 zile în circumstanțe excepționale.
Frecventa reactiilor adverse este definita utilizand urmatoarea
conventie:
- Foarte frecvente (mai mult de 1 din 10 animale tratate care prezinta
reactii adverse )
- Frecve
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

สรุปลักษณะสินค้า

                                1
ANEXA I
REZUMATUL CARACTERISTICILOR PRODUSULUI
1.
DENUMIREA PRODUSULUI MEDICINAL VETERINAR
Equilis Prequenza, suspensie injectabilă pentru cai.
2.
COMPOZIŢIA CALITATIVĂ ŞI CANTITATIVĂ
Fiecare doza de 1 ml conține:
SUBSTANŢĂ ACTIVĂ
:
Tulpini de virus al Influentei ecvine:
A/equine-2/ South Africa/4/03
50 UA
1
A/equine-2/ Newmarket/2/93
50 UA
Adjuvant
Iscom-Matrix conținând:
Saponină purificată
375 micrograme
Colesterol
125
micrograme
Fosfatidilcolină
62.5
micrograme
Pentru lista completă a excipienţilor, vezi secţiunea 6.1.
3.
FORMA FARMACEUTICĂ
Suspensie injectabilă .
Suspensie clară opalescentă.
4.
PARTICULARITĂŢI CLINICE
4.1
SPECII ŢINTĂ
Cai
4.2
INDICAŢII PENTRU UTILIZARE, SPECIFICAREA SPECIILOR ŢINTĂ
Imunizarea activă a cailor începând cu vârsta de 6 luni împotriva
influenţei pentru reducerea semnelor
clinice şi excreţiei de virus după infecţie.
Influenţa
Debutul imunităţii: 2 săptămâni după vaccinarea primară
Durata imunităţii:
5 luni după imunizarea primară
12 luni după prima revaccinare
4.3
CONTRAINDICAŢII
Nu sunt.
4.4
ATENŢIONĂRI SPECIALE PENTRU FIECARE SPECIE ŢINTĂ
Mânjii nu se vaccinează înaintea vârstei de 6 luni mai ales dacă
provin de la iepe care au fost
revaccinate în ultimele 2 luni de gestaţie, datorită posibilei
interferenţe cu anticorpii maternali
.
Vaccinati doar animalele sanatoase.
4.5
PRECAUŢII SPECIALE PENTRU UTILIZARE
Precauţii speciale pentru utilizare la animale
Nu este cazul
Precauţii speciale care trebuie luate de persoana care administrează
produsul medicinal la animale
În caz de auto-injectare accidentală solicitaţi imediat sfatul
medicului şi prezentaţi medicului
prospectul sau eticheta produsului.
4.6
REACŢII ADVERSE (FRECVENŢĂ ŞI GRAVITATE)
Poate apare rar o tumefacţie difuză dură sau moale la locul
injectării (max. 5 cm diametru) ce
regresează în 2 zile.
Poate apare rareori o tumefacţie difuză dură sau moale la locul
injectării (max. 5 cm diametru) ce
regresează în 2 zile. Durerea la locul
                                
                                อ่านเอกสารฉบับเต็ม
                                
                            

เอกสารเป็นภาษาอื่น

แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย บัลแกเรีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า บัลแกเรีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เดนมาร์ก 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เยอรมัน 16-12-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย เอสโตเนีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า เอสโตเนีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อังกฤษ 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฝรั่งเศส 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า อิตาลี 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลัตเวีย 16-12-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ลิทัวเนีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ลิทัวเนีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฮังการี 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปแลนด์ 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า โปรตุเกส 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวัก 16-12-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย สโลวีเนีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สโลวีเนีย 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ฟินแลนด์ 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า สวีเดน 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า นอร์เวย์ 16-12-2020
แผ่นพับข้อมูลผู้ป่วย แผ่นพับข้อมูลผู้ป่วย ไอซ์แลนด์ 16-12-2020
สรุปลักษณะสินค้า สรุปลักษณะสินค้า ไอซ์แลนด์ 16-12-2020

ค้นหาการแจ้งเตือนที่เกี่ยวข้องกับผลิตภัณฑ์นี้

ดูประวัติเอกสาร